Section 03
Market Analysis
$7.8T longevity economy — nobody owns the middle market
TL;DR
The longevity market will be worth $7.8 trillion by 2030. The biggest players either do testing OR treatment, but nobody does both affordably. Function Health is worth $2.5 billion with 100K members doing blood tests — but they can't treat you. Lifeforce treats you but barely tests. Fountain Life does both but costs $20K/year. BioForge owns the gap: real testing AND real treatment, starting at $365/year. The men's fitness segment is the highest-value customer base — they stick with protocols, buy multiple products, and tell their friends.
Total Addressable Market
$40M
SOM
$7.8T
TAM
$12.4B
SAM
Total Addressable
Global longevity economy by 2030 — encompassing diagnostics, therapeutics, digital health, supplements, and wellness
Serviceable Available
US + UAE + EU male longevity market: DTC/telehealth diagnostics + peptide therapy + AI health platforms for men 30-55 who actively train
Serviceable Obtainable
Year 5 target — blended revenue from quiz-to-elite value ladder with 30,000+ active users across all tiers
Market Segments
Blood Work & Diagnostics
Blood panels (100+ biomarkers), DNA tests, AI health analysis. Gateway product — $365/year with 75-85% margins. Function Health proved the model at $2.5B valuation.
Recovery & Healing Peptides
BPC-157, TB-500 — #1 demand from men who train hard. Tendon, joint, muscle recovery. Prescription-based recurring revenue.
Performance & Body Composition
CJC-1295+Ipamorelin (GH optimization), semaglutide (cutting/recomp), AI-powered training and nutrition. Core of the male fitness stack.
Longevity & Anti-Aging
Epitalon (telomeres), GHK-Cu (tissue renewal), Thymosin Alpha-1 (immune), comprehensive longevity protocols. Growing fastest among high-income men.
Digital Health & AI
AI-powered food/lifestyle/training recommendations via app. $29/mo subscription. Fastest-growing segment with lowest delivery cost.
Competitive Landscape
| Company | Revenue | Employees | Model | Margin | Peptides |
|---|---|---|---|---|---|
| Function Health | $2.5B valuation | 100+ | Blood testing platform, 100+ biomarkers, $365/yr | Est. 70-80% gross | ✗ |
| Lifeforce | Est. $50-100M | 200+ | Tony Robbins partnership, $129-149/mo, treatment + coaching | Est. 50-60% gross | ✓ |
| Fountain Life | Est. $50-100M | 300+ | Luxury longevity clinics, $20K/yr, full diagnostics + treatment | Est. 40-50% gross | ✓ |
| Prenuvo | $100M+ | 300+ | Full-body MRI scans, $999-2,499 per scan | Est. 40-50% gross | ✗ |
| 10X Health (Grant Cardone / Gary Brecka) | Est. $50-100M | 100+ | Franchise model, gene testing + supplements, $500-5K | Est. 60-70% gross | ✗ |
| Hone Health | Est. $30-50M | 100+ | Men's health telehealth, $65 entry, hormone optimization | Est. 50-60% gross | ✗ |
| Marek Health (MPMD Community) | Est. $20-40M | Est. 30-50 | Comprehensive men's health, $3.5-7K/yr, blood work + treatment | Est. 50-60% gross | ✓ |
| Hims & Hers | $2.4B (2025) | 2,442 | Full-stack telehealth, own prescribers | 5.5% net | ✓ |
| Medvi | $401M (2025) | 2 | Thin-layer telehealth via CareValidate/OpenLoop | 16.2% net | ✗ |
| AgelessRx | Est. $10-20M | Est. 20-30 | Cheapest peptide prescriptions online | Est. 40-50% gross | ✓ |
| BioForge (Target) | $48M (Y5) | 8-12 | Thin-layer, multi-market | 22% net (target) | ✓ |
The longevity market has a massive gap in the middle. Function Health proved testing demand at $2.5B valuation but can't treat. Lifeforce/Marek treat but have weak diagnostics. Fountain Life does both but costs $20K/year. Nobody owns the $500-$3,000/year sweet spot with BOTH comprehensive testing AND treatment. BioForge fills this exact gap — blood work with 100+ biomarkers at $365/year as the gateway, then peptide therapy, then full longevity protocols. Men who train are the highest-LTV customers: they stick with protocols, stack multiple products, and have strong community word-of-mouth.